News NanoViricides, Inc.

Equities

NNVC

US6300873022

Real-time Estimate Cboe BZX Other stock markets 11:17:53 2024-04-25 am EDT			5-day change	1st Jan Change
1.115 ^USD	-3.04%		-5.53%	+8.82%

Feb. 14	NanoViricides, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	CI
Feb. 01	NanoViricides, Inc. Announces Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as Antibiotics	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

NanoViricides: Fiscal Q2 Earnings Snapshot	Feb. 14	AQ
NanoViricides, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	Feb. 14	CI
Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications beyond COVID Treatment, Explains NanoViricides, NV-387 Could be As Revolutionary as Antibiotics	Feb. 02	AQ
NanoViricides, Inc. Announces Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as Antibiotics	Feb. 01	CI
Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides	Jan. 30	AQ
Nanoviricides, Inc. Reports Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the Nanoviricides Ultra-Broad-Spectrum Antiviral Drug Nv-2 with No Adverse Events Found	Jan. 29	CI
NanoViricides updates progress on Phase 1a/1b clinical trial of antiviral drug candidate NV-387	Nov. 29	AQ
NanoViricides, Inc. Announces the Single-Ascending Dose Part of the Phase 1A/1B Human Clinical Trial of NV-CoV-2	Nov. 28	CI
NanoViricides Has Filed its Quarterly Report, NV-387 Broad-Spectrum Antiviral in Clinical Trials Has Additional Applications	Nov. 16	AQ
NanoViricides, Inc. - Broad-Spectrum Antiviral NV-387 in Phase 1a/1b Clinical Trial is Highly Effective in an Animal Model for MPox and Smallpox Drug Development	Nov. 15	AQ
NanoViricides: Fiscal Q1 Earnings Snapshot	Nov. 15	AQ
NanoViricides, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	Nov. 14	CI
Nanoviricides, Inc. Announces Broad-Spectrum Antiviral Nv-387 (Nv-Cov-2) in Phase 1A/1B Clinical Trial Is Highly Effective in an Animal Model for Mpox and Smallpox Drug Development	Nov. 14	CI
North American Morning Briefing : Geopolitical -2-	23-10-18	DJ
NanoViricides, Inc. Has Filed its Annual Report	23-10-17	AQ
NanoViricides, Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	23-10-13	CI
North American Morning Briefing : Stock Futures -2-	23-10-11	DJ
Multi-Billion Dollar Treatment Market For Lung Infection That Causes Over 200,000 Hospitalizations Annually With Elderly, Young At Most Risk Has Game-Changing New Entrant	23-09-27	AQ
NanoViricides progressing well with new Covid study	23-08-31	AQ
The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company's Broad-Spectrum Antiviral Drug, is Progressing Successfully, Reports NanoViricides	23-08-22	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News NanoViricides, Inc.

Equities

NNVC

US6300873022

Summary

Filters